Article
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
Clinical pharmacology and therapeutics - 1 May 2018
Goetz Matthew P, Sangkuhl Katrin, Guchelaar Henk-Jan, Schwab Matthias, Province Michael, Whirl-Carrillo Michelle, Symmans W Fraser, McLeod Howard L, Ratain Mark J, Zembutsu Hitoshi, Gaedigk Andrea, van Schaik Ron H, Ingle James N, Caudle Kelly E, Klein Teri E
Abstract excerpt
Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast...
Topics
Join the communities discussing this publication.